top of page

Top selling drugs of 2024 | Best selling drugs of 2024 | iPharmaCenter

Updated: 2 days ago


Sl No

Brand

Q1 Revenues

1

Keytruda

$6.9 billion

2

Ozempic

$4.0 billion

3

Dupixent

$3.4 billion

4

Biktarvy

$3.0 billion

5

Darzalex

$2.7 billion

6

Stelara

$2.5 billion

7

Humira

$2.3 billion

8

Gardasil

$2.2 billion

9

Opdivo

$2.1 billion

10

Skyrizi

$2.0 billion


Top selling drugs/pharmaceuticals | 2024

1. Keytruda (Pembrolizumab)

  • Approved for: Keytruda is approved for treating various types of cancer, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, and more.

  • Manufacturer: Merck & Co., Inc.

  • Mechanism of Action: Keytruda is a monoclonal antibody that works by targeting and blocking the PD-1 (programmed death receptor-1) protein on the surface of T-cells. This inhibition boosts the immune system's ability to detect and destroy cancer cells.


2. Ozempic (Semaglutide)

  • Approved for: Ozempic is approved for managing type 2 diabetes and reducing the risk of major cardiovascular events in adults with type 2 diabetes and known heart disease.

  • Manufacturer: Novo Nordisk

  • Mechanism of Action: Ozempic is a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the action of the natural hormone GLP-1, enhancing insulin secretion, suppressing glucagon secretion, and slowing gastric emptying, which together helps control blood sugar levels.


3. Dupixent (Dupilumab)

  • Approved for: Dupixent is approved for the treatment of moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.

  • Manufacturer: Regeneron Pharmaceuticals and Sanofi

  • Mechanism of Action: Dupixent is a monoclonal antibody that inhibits the signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two key cytokines involved in the inflammatory response in various allergic and atopic diseases.


4. Biktarvy (Bictegravir/Emtricitabine/Tenofovir alafenamide)

  • Approved for: Biktarvy is approved for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg.

  • Manufacturer: Gilead Sciences

  • Mechanism of Action: Biktarvy combines three antiretroviral drugs: bictegravir (an integrase strand transfer inhibitor), emtricitabine, and tenofovir alafenamide (both nucleoside reverse transcriptase inhibitors), which together inhibit viral replication at different stages.


5. Darzalex (Daratumumab)

  • Approved for: Darzalex is approved for treating multiple myeloma, either as a monotherapy or in combination with other therapies.

  • Manufacturer: Janssen Biotech, Inc.

  • Mechanism of Action: Darzalex is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells, leading to the destruction of these cancer cells via immune-mediated mechanisms.


6. Stelara (Ustekinumab)

  • Approved for: Stelara is approved for treating moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

  • Manufacturer: Janssen Biotech, Inc.

  • Mechanism of Action: Stelara is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), cytokines that are involved in inflammatory and immune responses, thereby reducing inflammation and autoimmune reactions.


7. Humira (Adalimumab)

  • Approved for: Humira is approved

  • for treating a variety of inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and juvenile idiopathic arthritis.

  • Manufacturer: AbbVie Inc.

  • Mechanism of Action: Humira is a TNF (tumor necrosis factor) inhibitor. It binds to TNF-alpha, a pro-inflammatory cytokine, blocking its interaction with TNF receptors, thereby reducing inflammation and altering the immune response.


8. Gardasil (Human Papillomavirus Vaccine)

  • Approved for: Gardasil is approved for the prevention of diseases caused by human papillomavirus (HPV) types, including cervical, vulvar, vaginal, and anal cancers, genital warts, and precancerous or dysplastic lesions.

  • Manufacturer: Merck & Co., Inc.

  • Mechanism of Action: Gardasil is a vaccine that contains virus-like particles (VLPs) of the L1 protein from various HPV types. It stimulates an immune response against HPV, helping to prevent infection and the development of HPV-related diseases.


9. Opdivo (Nivolumab)

  • Approved for: Opdivo is approved for treating multiple types of cancer, including melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, and more.

  • Manufacturer: Bristol-Myers Squibb

  • Mechanism of Action: Opdivo is a monoclonal antibody that inhibits the PD-1 receptor on T-cells. By blocking this receptor, Opdivo enhances the immune system's ability to recognize and attack cancer cells.


10. Skyrizi (Risankizumab)

  • Approved for: Skyrizi is approved for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis.

  • Manufacturer: AbbVie Inc.

  • Mechanism of Action: Skyrizi is a monoclonal antibody that selectively targets and inhibits interleukin-23 (IL-23), a cytokine involved in the inflammatory process of psoriasis. By blocking IL-23, Skyrizi reduces inflammation and the symptoms of psoriasis.

0 comments

Recent Posts

See All

ความคิดเห็น


bottom of page